Export 8 results:
Author [ Title(Desc)] Type Year
Filters: Author is Mendizabal, Adam M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
R. F. Ambinder, Wu, J., Logan, B., Durand, C. M., Shields, R., Popat, U. R., Little, R. F., McMahon, D. K., Cyktor, J., Mellors, J. W., Ayala, E., Kaplan, L. D., Noy, A., Jones, R. J., Howard, A., Forman, S. J., Porter, D., Arce-Lara, C., Shaughnessy, P., Sproat, L., Hashmi, S. K., Mendizabal, A. M., Horowitz, M. M., Navarro, W. H., and Alvarnas, J. C., “Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.”, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
C
J. M. Hare, Fishman, J. E., Gerstenblith, G., Velazquez, D. L. DiFede, Zambrano, J. P., Suncion, V. Y., Tracy, M., Ghersin, E., Johnston, P. V., Brinker, J. A., Breton, E., Davis-Sproul, J., Schulman, I. H., Byrnes, J., Mendizabal, A. M., Lowery, M. H., Rouy, D., Altman, P., Foo, C. Wong Po, Ruiz, P., Amador, A., Da Silva, J., McNiece, I. K., Heldman, A. W., George, R., and Lardo, A., “Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.”, JAMA, vol. 308, no. 22, pp. 2369-79, 2012.
D
V. Y. Suncion, Ghersin, E., Fishman, J. E., Zambrano, J. Pablo, Karantalis, V., Mandel, N., Nelson, K. H., Gerstenblith, G., Velazquez, D. L. DiFede, Breton, E., Sitammagari, K., Schulman, I. H., Taldone, S. N., Williams, A. R., Sanina, C., Johnston, P. V., Brinker, J., Altman, P., Mushtaq, M., Trachtenberg, B., Mendizabal, A. M., Tracy, M., Da Silva, J., McNiece, I. K., Lardo, A. C., George, R. T., Hare, J. M., and Heldman, A. W., “Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.”, Circ Res, vol. 114, no. 8, pp. 1292-301, 2014.
M
B. L. Scott, Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Le-Rademacher, J., Mendizabal, A. M., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.”, J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
P
J. Bolaños-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., “Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.”, Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
K. Ballen, Mendizabal, A. M., Cutler, C., Politikos, I., Jamieson, K., Shpall, E. J., Dey, B. R., Attar, E., McAfee, S., Delaney, C., McCarthy, P., Ball, E. D., Kamble, R., Avigan, D., Maziarz, R. T., Ho, V. T., Koreth, J., Alyea, E., Soiffer, R., Wingard, J. R., Boussiotis, V., Spitzer, T. R., and Antin, J. H., “Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.”, Biol Blood Marrow Transplant, vol. 18, no. 12, pp. 1851-8, 2012.
R
J. R. Wingard, Carter, S. L., Walsh, T. J., Kurtzberg, J., Small, T. N., Baden, L. R., Gersten, I. D., Mendizabal, A. M., Leather, H. L., Confer, D. L., Maziarz, R. T., Stadtmauer, E. A., Bolaños-Meade, J., Brown, J., Dipersio, J. F., Boeckh, M., and Marr, K. A., “Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.”, Blood, vol. 116, no. 24, pp. 5111-8, 2010.
A. M. Mendizabal, Garcia-Gonzalez, P., and Levine, P. H., “Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries.”, Cancer Epidemiol, vol. 37, no. 3, pp. 247-54, 2013.